research use only
Cat.No.S9046
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase |
|---|---|
| Other Alkylating Agent Inhibitors | MNNG (1-Methyl-3-nitro-1-nitrosoguanidine) |
|
In vitro |
DMSO
: 22.5 mg/mL
(66.89 mM)
Ethanol : 5 mg/mL Water : 1 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 336.36 | Formula | C20H18NO4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2086-83-1 | -- | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| In vitro |
In 3T3-L1 adipocytes, the treatment of 12 μM or 20 μM berberine combined with 25 μM resveratrol shows more significant inhibition of lipid accumulation compared with individual compounds. The combination of this compound with resveratrol significantly increases the low-density-lipoprotein receptor expression in HepG2 cells to a level about one-fold higher in comparison to individual compounds. |
|---|---|
| In vivo |
The combination of Berberine and resveratrol exerts a significant enhanced effect on lipid-lowering in hyperlipidemic mice and intracellular lipid accumulation-decreasing in adipocytes as compared to individual agent alone, which is closely associated with SIRT1 and LDLR. |
References |
(data from https://clinicaltrials.gov, updated on 2026-04-21)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07541898 | NOT_YET_RECRUITING | Cardiometabolic Syndrome |
University of Central Lancashire |
2026-07-01 | |
| NCT07440147 | RECRUITING | Obesity & Overweight; Circadian Rhythm Disorders; Gut Microbiota Modulation; Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) |
FH Joanneum Gesellschaft mbH |
2026-01-20 | |
| NCT07465575 | NOT_YET_RECRUITING | Polycystic Ovary Syndrome |
Liaquat University of Medical & Health Sciences |
2026-03-16 | |
| NCT05749874 | ACTIVE_NOT_RECRUITING | PreDiabetes; Abdominal Obesity; Hypertension; Dyslipidemias; Atherosclerotic Cardiovascular Disease |
China National Center for Cardiovascular Diseases |
2023-10-31 | PHASE4 |
| NCT07129460 | NOT_YET_RECRUITING | Gastric Intestinal Metaplasia |
Xijing Hospital of Digestive Diseases |
2025-10-01 | PHASE4 |
| NCT05105321 | NOT_YET_RECRUITING | Metabolic Syndrome |
Tang Yida |
2021-12 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.